AKT1 and neoplasm: Examples include poly (ADP-ribose) polymerase inhibitors (PARPis) for homologous recombination repair (HRR) loss and protein kinase B (AKT) pathway inhibitors for treating tumours with phosphatase and tensin homologue (PTEN) loss [11, 12••].